Skip to main content

Table 1 Characteristics of the included studies

From: The efficacy and safety of minocycline as adjuvant therapy in refractory mycoplasma pneumonia in Chinese children: a meta-analysis

Study

Sample size

(C/E)

Age

(C/E; y)

Man (%)

Course of disease

(C/E; d)

Treatment

(C/E)

Therapeutic time(week)

Wang Bo,2013

35

10.3 ± 3.9

36(51.4)

NR

azithromycin10mg/Kg·d; minocycline4mg/Kg·d

1

 

35

9.4 ± 4.5

azithromycin10mg/Kg/d

Yi Qiaoling,2013

28

12.3 ± 3.8

29(51.8)

NR

erythromycin、azithromycin30-50 mg/Kg·d; minocycline4mg/Kg·d

1

 

28

12.6 ± 3.9

erythromycin、azithromycin30-50 mg/Kg·d

Zheng Qingkai,2018

40

11.1(8–14)

48(60.0)

NR

azithromycin10mg/Kg·d; minocycline4mg/Kg·d

1

 

40

10.7(7–13)

azithromycin10mg/Kg·d

Liang Zou,2016

23

11.4 ± 2.7

25(54.3)

NR

azithromycin2mg/mL·d; minocycline4mg/Kg·d

1

 

23

12.5 ± 2.6

azithromycin2mg/mL·d

Chen Ying,2012

20

11.6 ± 2.1

19(47.5)

NR

erythromycin、azithromycin; minocycline4mg/Kg·d

1

 

20

erythromycin、azithromycin

Wang Yongxia,2013

19

10.47 ± 1.98

20(54.1)

NR

azithromycin10mg/Kg·d; minocycline4mg/Kg·d

4

 

18

10.41 ± 1.98

azithromycin10mg/Kg/d

Rao Fuguang,2016

44

8.9 ± 1.7

51(58.0)

2.4 ± 0.9

azithromycin10mg/Kg·d; minocycline4mg/Kg·d

4

 

44

8.6 ± 2.2

2.2 ± 0.7

azithromycin10mg/Kg/d

Huang Wei,2018

40

6.51 ± 1.50

49(61.3)

12.30 ± 1.25

azithromycin10mg/Kg·d; minocycline4mg/Kg·d

4

 

40

7.62 ± 1.41

13.12 ± 1.06

azithromycin10mg/Kg/d

Sun Xiangyang,2016

120

9.6 ± 1.9

58(48.3)

5.8 ± 1.2

azithromycin10mg/Kg/d, minocycline 50 mg, twice a day

Discontinue 2 days after fever subsides

 

120

9.8 ± 2.0

56(46.7)

6.0 ± 1.3

azithromycin10mg/Kg/d

Xu Xiaohong,2017

60

9.2 ± 2.1

32(50.3)

NR

azithromycin10mg/Kg/d, minocycline 50 mg, twice a day

Discontinue 2 days after fever subsides

 

60

8.9 ± 2.4

33(55.0)

azithromycin10mg/Kg/d

  1. C Control group, E Experimental group, NR Not reported